PBPH vs XPH

PBPHBPortfolio Building Block World Pharma and Biotech Index ETF

XPHBState Street SPDR S&P Pharmaceuticals ETF

In short

PBPH Most biotech funds stop at the US border. PBPH buys the developed world's drug complex, pharma and biotech together, through a plain index fund charging 0.13%.

XPH Most pharma funds are a mega-cap sandwich. XPH equal-weights instead, so a small-cap drugmaker gets roughly the same say as an industry giant, across about 60 names, for 0.35% a year.

Stated mandate

PBPH The Fund seeks to track, before fees and expenses, the performance of the BITA Global Pharma and Biotech Select Index.

XPH The fund seeks to provide exposure to the pharmaceuticals segment of the S&P TMI.

Why people hold it

• PBPH 0.13% a year, in a global thematic aisle where the typical fund charges several times that. Fee drag is about as small as this shelf gets.
• Pharma and biotech under one ticker, global rather than US-only, so overseas drugmakers sit alongside the American names.portfoliobuildingblocketfs.com
• Straight index replication inside an ordinary 1940 Act fund. Published rules do the picking, not a manager's hunch.
• Cheap build plus workable trading puts it among the stronger implementations in its global thematic peer group.

• XPH Modified equal weighting with quarterly rebalances: the index trims what has run and keeps real room for small and mid-cap drugmakers, not just the household names.ssga.com
• At 0.35%, the cheapest sticker in its pharma peer group and well under the group median of 0.57% (PPH 0.36%, IHE 0.37%, PJP 0.57%, FTXH 0.60%).
• Pure pharma, not a health care grab bag: it draws only from the pharmaceuticals segment of the S&P Total Market Index. No insurers, hospitals or device makers.ssga.com
• Running since 2006 under a single index rulebook, with assets in the mid-size range and about 60 holdings behind it.

Worth knowing

• PBPH One industry, one storyline. Drug pricing rules, patent cliffs and trial readouts swing this basket in ways the broad market does not feel.
• Launched in late 2025, so there is no long live record showing how closely it hugs the index across a full cycle.
• Cash comes back once or twice a year, not monthly. This is an exposure holding, not an income schedule.

• XPH Equal weighting pulls the portfolio down the cap ladder, where trial results and FDA decisions can swing a single stock hard. Expect a bumpier ride than mega-cap pharma.ssga.com
• One industry, one country. Drug pricing rules and patent cliffs hit the whole basket at once.
• Moderately traded rather than a volume monster, so spreads can widen. Limit orders are the usual answer.

Full PBPH profile⁠

Full XPH profile⁠